Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • Bimekizumab: Phase Ib data

    UCB Group (Euronext:UCB), Brussels, Belgium Product: Bimekizumab (UCB4940) Business: Autoimmune Molecular target: Interleukin-17A (IL-17A); Interleukin-17F (IL-17F) Description: Humanized IgG1 mAb targeting IL-17A and …

    Published on 7/25/2016
  • Biosimilar insulin glargine: Phase III data

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Samsung Group, Seoul, South Korea Product: Biosimilar insulin glargine (MK-1293) Business: Endocrine/Metabolic Molecular target: …

    Published on 7/25/2016
  • Biosimilar insulin glargine: Phase III data

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Samsung Group, Seoul, South Korea Product: Biosimilar insulin glargine (MK-1293) Business: Endocrine/Metabolic Molecular target: …

    Published on 7/25/2016
  • Biosimilar trastuzumab: Phase III data

    Allergan plc (NYSE:AGN), Dublin, Ireland Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Product: Biosimilar trastuzumab (ABP 980) Business: Cancer Molecular target: …

    Published on 7/25/2016
  • Blisibimod: Interim Phase II data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Anthera Pharmaceuticals Inc. (NASDAQ:ANTH), Hayward, Calif. Product: Blisibimod (A-623) (formerly AMG 623) Business: Renal Molecular target: BLyS (BAFF) Description: …

    Published on 7/25/2016
  • Brigatinib: Updated Phase II data

    Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Cambridge, Mass. Product: Brigatinib (AP26113) Business: Cancer Molecular target: Anaplastic lymphoma kinase (ALK); Epidermal growth factor receptor (EGFR) Description: Dual …

    Published on 7/25/2016
  • Celecoxib/amlodipine besylate: Additional Phase III data

    Kitov Pharmaceuticals Holdings Ltd. (Tel Aviv:KTOV; NASDAQ:KTOV), Tel Aviv, Israel Product: Celecoxib/amlodipine besylate (KIT-302) Business: Cardiovascular Molecular target: Cyclooxygenase-2 (COX-2); Calcium channel …

    Published on 7/25/2016
  • DPX-RSV: Interim Phase I data

    Immunovaccine Inc. (TSX:IMV), Halifax, Nova Scotia Product: DPX-RSV Business: Infectious Molecular target: NA Description: Vaccine containing respiratory syncytial virus (RSV) SHe antigen and formulated with the DepoVax…

    Published on 7/25/2016
  • EndoBarrier Gastrointestinal Liner: Pivotal trial final data

    GI Dynamics Inc. (ASX:GID), Lexington, Mass. Product: EndoBarrier Gastrointestinal Liner Business: Endocrine/Metabolic Molecular target: NA Description: Non-surgical liner endoscopically placed in the GI tract to create…

    Published on 7/25/2016
  • Erbitux cetuximab: Additional Phase III data

    Merck KGaA (Xetra:MRK), Darmstadt, Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Erbitux cetuximab Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR) Description: Chimeric …

    Published on 7/25/2016
  • EVK-001: Phase III data

    Evoke Pharma Inc. (NASDAQ:EVOK), San Diego, Calif. Product: EVK-001 Business: Gastrointestinal Molecular target: Dopamine D2 receptor Description: Intranasal formulation of metoclopramide, a dopamine D2 receptor …

    Published on 7/25/2016
  • Gazyva: Phase III data

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Genentech Inc., South San Francisco, Calif. Chugai Pharmaceutical Co. Ltd. (Tokyo:4519), Tokyo, Japan Nippon Shinyaku Co. Ltd. (Tokyo:4516), Kyoto, Japan Roche (SIX:ROG; OTCQX…

    Published on 7/25/2016
  • IdeS: Additional Phase II data

    Hansa Medical AB (SSE:HMED), Lund, Sweden Product: IdeS Business: Transplant Molecular target: Immunoglobulin G (IgG) Description: Streptococcus pyogenes enzyme that cleaves IgG antibodies Indication: Prevent renal …

    Published on 7/25/2016
  • Lixisenatide/insulin glargine: Additional Phase III data

    Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Lixisenatide/insulin glargine (iGlarLixi, LixiLan) Business: Endocrine/Metabolic Molecular target: Glucagon-like …

    Published on 7/25/2016
  • Lixisenatide/insulin glargine: Additional Phase III data

    Zealand Pharma A/S (CSE:ZEAL), Glostrup, Denmark Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Product: Lixisenatide/insulin glargine (iGlarLixi, LixiLan) Business: Endocrine/Metabolic Molecular target: Glucagon-like …

    Published on 7/25/2016
  • OMS ElectroImmunotherapy: Preliminary Phase II data

    OncoSec Medical Inc. (NASDAQ:ONCS), San Diego, Calif. Product: OMS ElectroImmunotherapy, ImmunoPulse IL-12, DNA IL-12 Business: Cancer Molecular target: Interleukin-12 (IL-12) Description: DNA plasmid coding for IL-12 …

    Published on 7/25/2016
  • Tagrisso osimertinib: Phase III data

    AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Product: Tagrisso osimertinib (AZD9291) Business: Cancer Molecular target: Epidermal growth factor receptor (EGFR) Description: Oral irreversible inhibitor of EGFR-…

    Published on 7/25/2016
  • Tazemetostat: Preliminary Phase I/II data

    Epizyme Inc. (NASDAQ:EPZM), Cambridge, Mass. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Product: Tazemetostat (E7438, EPZ-6438) Business: Cancer Molecular target: Enhancer of zeste homolog 2 (EZH2) Description: Selective…

    Published on 7/25/2016
  • Trulicity dulaglutide: Phase III data

    Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Product: Trulicity dulaglutide (GLP-1Fc) (LY2189265) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R) Description: Long-…

    Published on 7/25/2016
  • Vadastuximab talirine: Additional Phase I data

    Seattle Genetics Inc. (NASDAQ:SGEN), Bothell, Wash. Product: Vadastuximab talirine (33A, SGN-CD33A) Business: Cancer Molecular target: CD33 Description: Humanized mAb against CD33 conjugated to 2 pyrrolobenzodiazepine (…

    Published on 7/25/2016
  • Xeljanz: Phase III data

    Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Xeljanz ( Jaquinus) tofacitinib Business: Autoimmune Molecular target: Janus kinase-3 (JAK-3); Janus kinase-1 (JAK-1) Description: Oral pan-Janus kinase (JAK) inhibitor …

    Published on 7/25/2016
  • ALXN1007: Interim Phase IIa data

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Product: ALXN1007 Business: Transplant Molecular target: Complement 5a (C5a) Description: Recombinant humanized mAb against complement 5a (C5a) Indication: …

    Published on 7/18/2016
  • Amantadine: Additional Phase III data

    Adamas Pharmaceuticals Inc. (NASDAQ:ADMS), Emeryville, Calif. Product: Amantadine (ADS-5102) Business: Neurology Molecular target: NA Description: Oral extended-release formulation of amantadine Indication: Treat …

    Published on 7/18/2016
  • Amantadine: Phase II data

    Adamas Pharmaceuticals Inc. (NASDAQ:ADMS), Emeryville, Calif. Product: Amantadine (ADS-5102) Business: Autoimmune Molecular target: NA Description: Oral extended-release formulation of amantadine Indication: Treat major…

    Published on 7/18/2016
  • ARGX-113: Phase I data

    argenx N.V. (Euronext:ARGX), Breda, the Netherlands Product: ARGX-113 Business: Autoimmune Molecular target: NA Description: Human antibody Fc fragment developed using ABDEG technology Indication: Treat IgG-mediated …

    Published on 7/18/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993